Molecular pathways: JAK/STAT pathway: Mutations, inhibitors, and resistance

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 1933-1940

  Quintás Cardama, Alfonso ^a   Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; BARICITINIB; BBT 594; FEDRATINIB; HETEROCHROMATIN PROTEIN 1; HETEROCHROMATIN PROTEIN 1 ALPHA; JANUS KINASE; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PANOBINOSTAT; PLACEBO; RUXOLITINIB; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOFACITINIB; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; AMINO ACID SUBSTITUTION; ANEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME INHIBITION; EPIGENETICS; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; HEMATOLOGIC MALIGNANCY; HISTONE PHOSPHORYLATION; HODGKIN DISEASE; HUMAN; LYMPHOMA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SOLID TUMOR; SOMATIC MUTATION; THROMBOCYTOPENIA;

DRUG RESISTANCE, NEOPLASM; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MODELS, BIOLOGICAL; MUTATION; MYELOPROLIFERATIVE DISORDERS; PYRAZOLES; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84877095601     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0284     Document Type: Review

References (85)

1. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93:397-409. (Pubitemid 28232084)
2. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-95. (Pubitemid 28232083)
3. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-83. (Pubitemid 47327415)
4. Silva M, Richard C, Benito A, Sanz C, Olalla I, Fernández-Luna JL. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med 1998;338:564-71. (Pubitemid 28114644)
5. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41:1-5. (Pubitemid 38657103)
6. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood 2002;100:4272-90. (Pubitemid 35429665)
7. Beer PA, Green AR. Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program 2009;621-8.
8. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood 2007;109:5104-11. (Pubitemid 46890524)
9. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelo fibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010;115:1703-8.
10. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-901.
11. Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010;45:458-63.
12. Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J, et al. The role of allogeneic SCT in primary myelofibrosis: a British society for blood and marrow transplantation study. Bone Marrow Transplant 2010;45:1587-93.
13. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffé M, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-12. (Pubitemid 27495745)
14. Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t (9;15;12) in a myeloid leukemia. Blood 1997;90:2535-40. (Pubitemid 27413461)
15. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-29. (Pubitemid 30017220)
16. Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips LA, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009;106:9414-8.
17. Bercovich D, Ganmore I, Scott LM, Wainreb G, Birger Y, Elimelech A, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008;372:1484-92.
18. Kearney L, Gonzalez De Castro D, Yeung J, Procter J, Horsley SW, Eguchi-Ishimae M, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009;113:646-8.
19. Xiang Z, Zhao Y, Mitaksov V, Kasai Y, Molitoris A, Ries RE, et al. Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 2008;111:4809-12.
20. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006;10:65-75.
21. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY, Rhim HS, et al. The JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2006;25:1434-6. (Pubitemid 43336473)
22. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, et al. JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3. (Pubitemid 41609167)
23. Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 2012;26:1140-3.
24. Joos S, Kupper M, Ohl S, von Bonin F, Mechtersheimer G, Bentz M, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res 2000;60:549-52. (Pubitemid 30094549)
25. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198:851-62. (Pubitemid 37152922)
26. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105:13520-5.
27. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012;30:1005-14.
28. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61. (Pubitemid 40386783)
29. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8. (Pubitemid 40663494)
30. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90. (Pubitemid 40570926)
31. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97. (Pubitemid 40544655)
32. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-92. (Pubitemid 40853184)
33. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008;112:2190-8.
34. Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med 2008;59:213-22. (Pubitemid 351287934)
35. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68. (Pubitemid 46193073)
36. Pietra D, Li S, Brisci A, Rumi E, Theocharides A, Ferrari M, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686-9. (Pubitemid 351213460)
37. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007;21:1960-3. (Pubitemid 47299970)
38. Wang YL, Vandris K, Jones A, Cross NC, Christos P, Adriano F, et al. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia 2008;22:1289. (Pubitemid 351833808)
39. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
40. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006;108:3472-6.
41. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844-7.
42. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008;112:141-9.
43. Bersenev A, Wu C, Balcerek J, Jing J, Kundu M, Blobel GA, et al. Lnk constrains myeloproliferative diseases in mice. J Clin Invest 2010;120:2058-69.
44. Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A 2006;103:6224-9.
45. Ishii T, Bruno E, Hoffman R, Xu M. Involvement of various hemato-poietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood 2006;108:3128-34.
46. Delhommeau F, Dupont S, Tonetti C, Masse A, Godin I, Le Couedic JP, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood 2007;109:71-7. (Pubitemid 46053046)
47. Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zamegar S, et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005;102:18962-7. (Pubitemid 43049549)
48. Jamieson CH, Barroga CF, Vainchenker WP. Miscreant myeloproliferative disorder stem cells. Leukemia 2008;22:2011-9.
49. Kota J, Caceres N, Constantinescu SN. Aberrant signal transduction pathways in myeloproliferative neoplasms. Leukemia 2008;22:1828-40.
50. Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115:3109-17.
51. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, et al. Ef ficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008;13:311-20. (Pubitemid 351446195)
52. Ugo V, Marzac C, Teyssandier I, Larbret F, Lecluse Y, Debili N, et al. Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol 2004;32:179-87. (Pubitemid 38177643)
53. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dimhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008;111:3931-40.
54. Xing S, Wanting TH, Zhao W, Ma J, Wang S, Xu X, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008;111:5109-17.
55. Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010;17:584-96.
56. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010;115:3589-97.
57. Dawson MA, Bannister AJ, Gottgens B, Foster SD, Bartke T, Green AR, et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009;461:819-22.
58. Liu F, Zhao X, Perna F, Koppikar P, Abdel-Wahab O, Harr MW, et al. JAK2 V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011;19:283-94.
59. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011;10:127-40.
60. Nussenzveig RH, Cortes J, Sever M, Quintas-Cardama A, Ault P, Manshouri T, et al. Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001. Int J Hematol 2009;90:58-63.
61. Verstovsek S, Kantarjian H, Mesa R, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of a JAK1 and JAK2 inhibitor, INCB018424, in myelofibrosis. N Engl J Med 2010;363:1117-27.
62. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366:799-807.
63. Verstovsek S, Mesa RA, Gotlib J, Levy R, Gupta V, DiPersio JF, et al. Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Blood 2012;120. Abstract nr 800.
64. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366:787-98.
65. Cervantes F, Kiladjian JJ, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuitty M, et al. Long-term safety, efficacy, and survival findings from comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Blood 2012;120. Abstract nr 800.
66. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011;29:789-96.
67. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone R, et al. SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. Blood 2011;118. Abstract nr 3838.
68. Talpaz M, Jamieson C, Gabrail NY, Lebedinsky C, Neumann F, Gao G, et al. A phase II randomized dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF. Blood 2012;120. Abstract nr 2837.
69. Pardanani A, Gotlib J, Gupta V, Roberts AW, Wadleigh M Sirhan S, et al. Phase I/II study of CYT387, a JAK1/JAK2 inhibitor for the treatment of myelofibrosis. Blood 2012;120. Abstract nr 178.
70. Pardanani A, George G, Lasho T, Hogan WJ, Litzow MR, Begna K, et al. A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 2010;116. Abstract nr 460.
71. Komrokji R, Wadleigh M, Seymour JF, Roberts AW, To LB, Zhu HJ, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Blood 2011;118. Abstract nr 282.
72. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, et al. Phase I study of a novel oral janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012;30:4161-7.
73. Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012;489:155-9.
74. Wang Y, Fiskus W, Chong DG, Buckley KM, Natarajan K, Rao R, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009;114:5024-33.
75. Guerini V, Barbui V, Spinelli O, Salvi A, Dellacasa C, Carobbio A, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F. Leukemia 2009;22:740-7. (Pubitemid 351552623)
76. Baffert F, Evrot E, Ebel N, Roelli C, Andraos R, Qian Z, et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease. Blood 2011;118. Abstract nr 798.
77. Manshouri T, Estrov Z, Quintas-Cardama A, Burger J, Zhang Y, Livun A, et al. Bone marrow stroma-secreted cytokines protect JAK2 (V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011;71:3831-40.
78. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128-38.
79. Pardanani A, Gotlib J, Jamieson C, Cortes J, Talpaz M, Stone R, et al. A phase I study of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden. Blood 2009;114. Abstract nr 755.
80. Verstovsek S, Odenike O, Scott B, Estrov Z, Cortes J, Thomas DA, et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood 2009;114. Abstract nr 3905.
81. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009;23:1441-5.
82. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010;115:5232-40.
83. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487-97.
84. Jiang JK, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino) piperi din-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem 2008;51:8012-8.
85. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298-307.